Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer
Aarif Siddiqui(Friedrich-Alexander-Universität Erlangen-Nürnberg), Paolo Ceppi(University of Southern Denmark), Özgür Şahin(MUSC Hollings Cancer Center), Ramakrishnan Natesan(University of Pennsylvania), Marco Volante(University of Turin), Beatrice Parma(Friedrich-Alexander-Universität Erlangen-Nürnberg), Vignesh Ramesh(University of Southern Denmark), Paolo Bironzo(University of Turin), Özge Saatci(Medical University of South Carolina), Harald Schuhwerk(International Council on Mining and Metals), Ida Rapa(University of Turin), Irfan A. Asangani(Penn Center for AIDS Research), Paradesi Naidu Gollavilli(Friedrich-Alexander-Universität Erlangen-Nürnberg), Maria Eleni Vazakidou(Friedrich-Alexander-Universität Erlangen-Nürnberg), Annemarie Schwab(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 49
Related Papers
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
|JAMA|2015|416
The role of CD95 and CD95 ligand in cancer
|Cell Death and Differentiation|2015|338
Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
|Oncogene|2012|286
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
|Journal of Clinical Oncology|2023|224
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
|Cancer Discovery|2023|181